381 related articles for article (PubMed ID: 29258378)
1. Hepatorenal syndrome: the clinical impact of vasoactive therapy.
Colle I; Laterre PF
Expert Rev Gastroenterol Hepatol; 2018 Feb; 12(2):173-188. PubMed ID: 29258378
[TBL] [Abstract][Full Text] [Related]
2. Terlipressin versus other vasoactive drugs for hepatorenal syndrome.
Israelsen M; Krag A; Allegretti AS; Jovani M; Goldin AH; Winter RW; Gluud LL
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011532. PubMed ID: 28953318
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis.
Facciorusso A; Chandar AK; Murad MH; Prokop LJ; Muscatiello N; Kamath PS; Singh S
Lancet Gastroenterol Hepatol; 2017 Feb; 2(2):94-102. PubMed ID: 28403995
[TBL] [Abstract][Full Text] [Related]
4. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study.
Ghosh S; Choudhary NS; Sharma AK; Singh B; Kumar P; Agarwal R; Sharma N; Bhalla A; Chawla YK; Singh V
Liver Int; 2013 Sep; 33(8):1187-93. PubMed ID: 23601499
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of terlipressin for hepatorenal syndrome: the United States hospital perspective.
Carter JA; Huang X; Jamil K; Corman S; Ektare V; Niewoehner J
J Med Econ; 2023; 26(1):1342-1348. PubMed ID: 37729445
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy of vasoconstrictor therapies for type 1 hepatorenal syndrome: a network meta-analysis.
Zheng JN; Han YJ; Zou TT; Zhou YJ; Sun DQ; Zhong JH; Braddock M; Zheng MH
Expert Rev Gastroenterol Hepatol; 2017 Nov; 11(11):1009-1018. PubMed ID: 28708431
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome.
Krag A; Borup T; Møller S; Bendtsen F
Adv Ther; 2008 Nov; 25(11):1105-40. PubMed ID: 19018483
[TBL] [Abstract][Full Text] [Related]
8. AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review.
Garcia-Tsao G; Abraldes JG; Rich NE; Wong VW
Gastroenterology; 2024 Jan; 166(1):202-210. PubMed ID: 37978969
[TBL] [Abstract][Full Text] [Related]
9. Vasoconstrictors in hepatorenal syndrome - A critical review.
Mattos ÂZ; Schacher FC; Mattos AA
Ann Hepatol; 2019; 18(2):287-290. PubMed ID: 31023616
[TBL] [Abstract][Full Text] [Related]
10. Terlipressin is superior to midodrine/octreotide for hepatorenal syndrome type 1.
Kalambokis GN; Baltayiannis G; Christodoulou D; Christou L
Eur J Gastroenterol Hepatol; 2017 Dec; 29(12):1428-1429. PubMed ID: 29111999
[No Abstract] [Full Text] [Related]
11. Noradrenaline or terlipressin for hepatorenal syndrome?
Celis P; Rada G
Medwave; 2015 Aug; 15 Suppl 2():e6235. PubMed ID: 26334297
[TBL] [Abstract][Full Text] [Related]
12. Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis.
Wang H; Liu A; Bo W; Feng X; Hu Y
Medicine (Baltimore); 2018 Apr; 97(16):e0431. PubMed ID: 29668606
[TBL] [Abstract][Full Text] [Related]
13. Results of pretransplant treatment of hepatorenal syndrome with terlipressin.
Solà E; Cárdenas A; Ginès P
Curr Opin Organ Transplant; 2013 Jun; 18(3):265-70. PubMed ID: 23652609
[TBL] [Abstract][Full Text] [Related]
14. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.
Sharma P; Kumar A; Shrama BC; Sarin SK
Am J Gastroenterol; 2008 Jul; 103(7):1689-97. PubMed ID: 18557715
[TBL] [Abstract][Full Text] [Related]
15. Terlipressin in hepatorenal syndrome: Evidence for present indications.
Rajekar H; Chawla Y
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():109-14. PubMed ID: 21199521
[TBL] [Abstract][Full Text] [Related]
16. Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials.
Fabrizi F; Dixit V; Messa P; Martin P
Int J Artif Organs; 2009 Mar; 32(3):133-40. PubMed ID: 19440988
[TBL] [Abstract][Full Text] [Related]
17. Hepatorenal Acute Kidney Injury and the Importance of Raising Mean Arterial Pressure.
Velez JC; Kadian M; Taburyanskaya M; Bohm NM; Delay TA; Karakala N; Rockey DC; Nietert PJ; Goodwin AJ; Whelan TP
Nephron; 2015; 131(3):191-201. PubMed ID: 26485256
[TBL] [Abstract][Full Text] [Related]
18. [Vasoconstrictors in the treatment of hepatorenal syndrome].
Ortega R; Calahorra B; Ginès P
Nefrologia; 2002; 22 Suppl 5():56-61. PubMed ID: 12107919
[No Abstract] [Full Text] [Related]
19. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond.
Moreau R; Lebrec D
Hepatology; 2006 Mar; 43(3):385-94. PubMed ID: 16496352
[TBL] [Abstract][Full Text] [Related]
20. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis.
Nassar Junior AP; Farias AQ; D' Albuquerque LA; Carrilho FJ; Malbouisson LM
PLoS One; 2014; 9(9):e107466. PubMed ID: 25203311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
